Evidence map›Paper›PMID 24530749›Full record

ArticleHuman immunology2014

Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus.

U De la Cruz-Mosso, R Bucala, C A Palafox-Sánchez, I Parra-Rojas, J R Padilla-Gutiérrez, A L Pereira-Suárez, H Rangel-Villalobos, M Vázquez-Villamar, L I Angel-Chávez, J F Muñoz-Valle

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. MIF contribution to progressive brain diseases.Journal of neuroinflammation · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Association AmongClinical, cosmetic and investigational dermatology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Genetic Variants of thePharmacogenomics and personalized medicine · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

U De la Cruz-MossoInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
R BucalaDepartment of Medicine/Section of Rheumatology, Yale University School of Medicine, New Haven, USA.
C A Palafox-SánchezInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
I Parra-RojasUnidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, Mexico.
J R Padilla-GutiérrezInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
A L Pereira-SuárezInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
H Rangel-VillalobosInstituto de Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
M Vázquez-VillamarInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
L I Angel-ChávezInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
J F Muñoz-ValleInstituto de Investigación en Ciencias Biomédicas/Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. Electronic address: biologiamolecular@hotmail.com.
Universidad de Guadalajara · MXUniversidad Autónoma de Guerrero · MXYale University · US

Funding

Mechanisms of Rheumatoid Synovial Fibroblast ActivationR01AR049610 · NIAMS · YALE UNIVERSITY · PI BUCALA, RICHARD J · 2002 to 2018
$5.0M
INNATE AND ADAPTIVE MECHANISMS IN ARTHRITISR01AR050498 · NIAMS · YALE UNIVERSITY · PI BUCALA, RICHARD J · 2004 to 2013
$3.6M
NIAMS NIH HHS AR-050498NIAMS NIH HHS R01 AR049610NIAMS NIH HHS R01 AR050498
6 · The paper itself

Abstract

Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine associated with the pathogenesis of autoimmune inflammatory diseases. There is evidence that MIF functions in a positive feedback loop with TNF-α that could perpetuate the inflammatory process in systemic lupus erythematosus (SLE). In this case-control study we investigated whether commonly occurring functional MIF polymorphisms are associated with SLE as well as with MIF and TNF-α serum levels in a Mexican-Mestizo population. Genotyping of the -794 CATT5-8 (rs5844572) and -173 G>C (rs755622) MIF polymorphisms was performed by PCR and PCR-RFLP, respectively in 186 SLE patients and 200 healthy subjects. MIF and TNF-α serum levels were determined by ELISA. A significant increase of MIF and TNF-α levels was found in SLE patients. According to a genetic model, we found a significant association of genotypes carrying the -794 CATT7 and -173(∗)C risk alleles with susceptibility to SLE and with a significant increase of TNF-α. In conclusion, MIF gene polymorphisms are associated with SLE susceptibility and with an increase of TNF-α serum levels in a Mexican-Mestizo population.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdolescentAdultAgedAllelesCase-Control StudiesFemaleGene FrequencyGenotypeHumansLupus Erythematosus, SystemicMacrophage Migration-Inhibitory FactorsMaleMexicoMiddle AgedMacrophage Migration-Inhibitory FactorsTumor Necrosis Factor-alpha

Identifiers

PMID24530749
PMCPMC4017948
OpenAlexW1987148136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.